Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Kaletra

Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 55–56

HOS-109015 · Präparat HOS-093083

55 Rifampicin Lopinavir: Co-administration of Kaletra with Large decreases in lopinavir rifampicin is not recommended as concentrations may be observed the decrease in lopinavir due to CYP3A induction by concentrations may in turn rifampicin. significantly decrease the lopinavir therapeutic effect. A dose adjustment of Kaletra 400 mg/400 mg (i.e. Kaletra 400/100 mg + ritonavir 300 mg) twice daily has allowed compensating for the CYP 3A4 inducer effect of rifampicin. However, such a dose adjustment might be associated with ALT/AST elevations and with increase in gastrointestinal disorders. Therefore, this co-administration should be avoided unless judged strictly necessary. If this co-administration is judged unavoidable, increased dose of Kaletra at 400 mg/400 mg twice daily may be administered with rifampicin under close safety and therapeutic drug monitoring. The Kaletra dose should be titrated upward only after rifampicin has been initiated (see section 4.4). Antipsychotics Lurasidone Due to CYP3A inhibition by The concomitant administration with lopinavir/ritonavir, concentrations lurasidone is contraindicated (see of lurasidone are expected to section 4.3). increase. Pimozide Due to CYP3A inhibition by Concomitant administration of lopinavir/ritonavir, concentrations Kaletra and pimozide is of pimozide are expected to contraindicated as it may increase the increase. risk of serious haematologic abnormalities or other serious adverse effects from this agent (see section 4.3) Quetiapine Due to CYP3A inhibition by Concomitant administration of lopinavir/ritonavir, concentrations Kaletra and quetiapine is of quetiapine are expected to contraindicated as it may increase increase. quetiapine-related toxicity.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) pimozide (HOS-085600) lurasidone (HOS-086148)